Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients

被引：23

作者：

Koch, Kevin M. ^{[1
]}

Im, Young-Hyuck ^{[2
]}

Kim, Sung-Bae ^{[3
]}

Ribate, Ander Urruticoechea ^{[4
]}

Stephenson, Joe ^{[5
]}

Botbyl, Jeffrey ^{[6
]}

Cartee, Leanne ^{[7
]}

Holshouser, Jane ^{[8
]}

Ridgway, Derry ^{[7
]}

机构：

[1] GlaxoSmithKline, Clin Pharmacol Modeling & Simulat, Res Triangle Pk, NC USA

[2] Samsung Med Ctr, Seoul, South Korea

[3] Asan Med Ctr, Seoul, South Korea

[4] Hosp Duran & Reynals, Inst Catala Oncol, Barcelona, Spain

[5] Canc Ctr Carolinas, Greenville, SC USA

[6] Provonix LLC, Cincinnati, OH USA

[7] GlaxoSmithKline, Oncol Drug Dev, London, England

[8] ICON Clin Res, Dublin, Ireland

来源：

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT | 2013年 / 2卷 / 04期

关键词：

esomeprazole; lapatinib; breast cancer; proton pump inhibitor; drug interaction;

D O I：

10.1002/cpdd.45

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The aqueous solubility of lapatinib declines significantly at pH>4, suggesting that its bioavailability might be lowered by acid-reducing drugs. A study was therefore conducted to assess the effects of esomeprazole on lapatinib pharmacokinetics (PK). Women with metastatic human epidermal growth factor receptor 2 positive (HER2(+)) breast cancer were enrolled. Patients received 1,250 mg lapatinib once daily (QD) in the morning on Days 1-7 (Period 1) and Days 8-14 (Period 2) with 40 mg esomeprazole QD at bedtime 3 hours after dinner on Days 8-14. Lapatinib PK sampling occurred during the 24-hour steady-state dosing intervals on Day 7 (lapatinib alone) and Day 14 (lapatinib with esomeprazole). Esomeprazole treatment resulted in decreased lapatinib bioavailability (mean 26%, range 6-49%) that was inversely associated with patient age as a significant covariate.

引用

页码：336 / 341

页数：6

共 50 条

[31] Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer
Bruno José Dumêt Fernandes
Carolina de Miranda Silva
Jurandyr Moreira Andrade
Ângelo do Carmo Silva Matthes
Eduardo Barbosa Coelho
Vera Lucia Lanchote
Cancer Chemotherapy and Pharmacology, 2011, 68 : 897 - 904
[32] A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study)
Fumoleau, Pierre
Koch, Kevin M.
Brain, Etienne
Lokiec, Francois
Rezai, Keyvan
Awada, Ahmad
Hayward, Larry
Werutsky, Gustavo
Bogaerts, Jan
Marreaud, Sandrine
Cardoso, Fatima
BREAST, 2014, 23 (05): : 663 - 669
[33] Combinatorial Effects of Lapatinib and Rapamycin in Triple-Negative Breast Cancer Cells
Liu, Tongrui
Yacoub, Rami
Taliaferro-Smith, LaTonia D.
Sun, Shi-Yong
Graham, Tisheeka R.
Dolan, Ryan
Lobo, Christine
Tighiouart, Mourad
Yang, Lily
Adams, Amy
O'Regan, Ruth M.
MOLECULAR CANCER THERAPEUTICS, 2011, 10 (08) : 1460 - 1469
[34] Lapatinib and trastuzumab: Molecular effects and efficacy, separately and combined in breast cancer.
Holmes, F. A.
Espina, V. A.
Liotta, L. A.
Nagarwala, Y. M.
Chang, J. C.
O'Shaughnessy, J.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[35] EFFECTS OF TRASTUZUMAB AND LAPATINIB ON HER2 POSITIVE BREAST CANCER TREATMENT
Jia, W.
Wang, T. Z.
JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2019, 33 (02): : 551 - 555
[36] Tolerability of lapatinib in combination with taxanes (T) in 507 patients with breast cancer (BC)
Crown, J.
Burris, H. A.
Di Leo, A.
Jagiello-Gruszfeld, A.
Jones, S.
LoRussos, P.
Oliva, C.
Parikh, R.
Stein, S.
Koehler, M.
EJC SUPPLEMENTS, 2008, 6 (07): : 200 - 200
[37] AUSTRALIAN BREAST CANCER PATIENTS ENROLLED IN THE LAPATINIB EXPANDED ACCESS PROGRAM (LEAP)
Lynch, J.
Boyle, F.
Wilkin, N.
Hague, C.
ANNALS OF ONCOLOGY, 2010, 21 : 102 - 102
[38] Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients
Rezai, Keyvan
Urien, S.
Isambert, N.
Roche, H.
Dieras, V.
Berille, J.
Bonneterre, J.
Brain, E.
Lokiec, F.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (06) : 1529 - 1536
[39] A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
Massimo Cristofanilli
Stephen R. D. Johnston
Alexey Manikhas
Henry L. Gomez
Oleg Gladkov
Zhimin Shao
Sufia Safina
Kimberly L. Blackwell
Ricardo H. Alvarez
Stephen D. Rubin
Sulabha Ranganathan
Suman Redhu
Maureen E. Trudeau
Breast Cancer Research and Treatment, 2013, 137 : 471 - 482
[40] Safety and tolerability of lapatinib in combination with taxanes (T) in patients with breast cancer (BC)
Crown, J. P.
Burris, H. A., III
Jones, S.
Koch, K. M.
Fittipaldo, A.
Parikh, R.
Koehler, M.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)

← 1 2 3 4 5 →